Get started
Live feed
·
INSIDERFilingvia Quantisnow
Calidi Biotherapeutics Inc. logo

Calidi Biotherapeutics (CLDI) director Peoples received 4,000 units

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

George Peoples (director at Calidi Biotherapeutics Inc., CLDI) reported that they received 4,000 units on Aug 17, 2026.

Reporting person
Peoples George

Options and other derivatives

Options and other derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Aug 17, 2026Grant or award (A)Non-Qualified Stock Options (right to buy)On 4,000 Common stock1, 2+4,000--4,000 direct

Holdings before and after

  • Non-Qualified Stock Options (right to buy): 0 to 4,000 direct

Footnotes from the filing

  1. 1. On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 4,000 shares of common stock (the Options ) at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.
  2. 2. Does not include the stock options previously granted to the Reporting Person.

Transaction codes in this filing

Grant or award:
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ

What did Peoples report in this CLDI Form 4?

George Peoples (director at Calidi Biotherapeutics Inc., CLDI) reported that they received 4,000 units on Aug 17, 2026.

What does transaction code A mean on an SEC Form 4?

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

Historical context for CLDI

Across the 27 sessions after earlier CLDI headlines, the stock closed higher 11 times and lower 15 times, with a median move of 3.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

CLDI close-to-close change in the session after earlier headlines
SessionEarlier headlineCLDISPY
Aug 14, 2026Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights+3.2%-0.2%
Jul 27, 2026Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference+9.5%+0.0%
Jul 21, 2026Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Driversand 1 other headline that session-13.9%+0.8%
Jul 9, 2026Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711+5.3%+0.8%
Jun 24, 2026Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit+0.6%-0.0%
Jun 16, 2026Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study-1.9%-0.6%

Earlier insider filings at CLDI

Quantisnow market dataAMEX
Calidi Biotherapeutics Inc. logo
CLDI
Calidi Biotherapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2021
Get push alerts for CLDI

Follow CLDI and get a push notification the moment its next story breaks.

Full CLDI profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLDI (Calidi Biotherapeutics Inc.) and more on Quantisnow.